What is FOXO4-DRI?
Experimental senolytic peptide. Highly experimental.
FOXO4-DRI is a peptide designed to induce apoptosis in senescent cells (senolytics). Very early research stage. One of the most experimental compounds in the longevity space.
What the evidence says
The overall evidence grade for FOXO4-DRI is C (limited — early or preliminary data, mostly mechanistic or animal). Extremely early-stage senolytic research.
Specific findings with supporting evidence:
- Designed as senolytic. Evidence grade C.
- Mouse studies exist. Evidence grade C.
Best-supported outcomes:
- Research interest only.
Where marketing outpaces evidence:
- The claim that "Human safety/efficacy established" is not supported by the evidence (grade C).
- Marketing often overstates: Reverses aging.
- Marketing often overstates: Proven senolytic.
Dose and timing
Take it in the morning. Highly experimental.
Who it's for, and who should skip it
Most relevant for:
- Research interest only.
Not appropriate for:
- Anyone - highly experimental.
Safety and cautions
Important: Highly experimental. Minimal human data. Important: Unknown risks. Long-term effects unknown. Important: Senolytic concerns. Killing cells has complex implications.
Common mistakes
- Self-experimenting.
- Believing it reverses aging.
Myths vs reality
A common misconception: FOXO4-DRI reverses aging in humans. In reality, mouse studies only; human effects unknown.
Questions people ask
What is a senolytic? A compound that selectively kills senescent (aging) cells.
Editorial note
This guide summarizes the published evidence on FOXO4-DRI. It is educational content, not medical advice. Confirm with your clinician if you take prescription medications or manage a chronic condition.